The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.
The drug is the first on-demand off episode treatment to be administered sublingually.
Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.
Helius’s short-term treatment PoNS device has been approved for use in Canada, and is intended to be used alongside physical therapy for gait deficit due to mild and moderate symptoms of MS.
Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Amid swirling reports of associations between stroke and the novel coronavirus, as well as the impact the pandemic has had on stroke care, new recommendations to maintain care expectations have been suggested by a diverse group of stroke experts.
Educational sessions led by experts in multiple sclerosis will be held May 26-29, 2020.
The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.
During the COVID-19 pandemic, it is more important than ever to ensure that a patient with stroke is transferred to the right hospital the first time around.
This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.